



2018 WORLD CONGRESS OF COMPOUNDING

Follow Us on Social Media



#WCC2018VEGAS



2018
**WORLD CONGRESS
OF COMPOUNDING**

CREATIVELY PERSONALIZING A CHRONIC PAIN MANAGEMENT PLAN

Anne Marie Pinard, MD

HOUSEKEEPING



Cell Phones



Download the Slides



Questions



**No photography,
audio, or video
recordings**

DISCLAIMER

DISCLAIMER: The information contained in this program, which may include treatment modalities, diagnostic and therapeutic information, and instructions related to regulatory guidelines and current standards of practice for pharmacy compounding, is FOR EDUCATIONAL PURPOSES ONLY and should not be taken as a treatment regimen, product indication, suggested treatment modality, or suggested standard of practice. NOTE TO MEDICAL OR ALLIED HEALTH PROFESSIONAL: Any treatments, therapies, or standards of practice must be fully investigated and prescribed by a duly licensed medical practitioner in accordance with accepted professional standards and compendia. Any regulatory or practice standard must be fully investigated by a licensed pharmacist in accordance with accepted professional practice standards and compendia.

ACCREDITATION

PHARMACIST & PHARMACY TECHNICIAN CREDITS



CPE Consultants, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education and complies with the Accreditation Standards for continuing education activities.

Activity Type	Pharmacist	Pharmacy Technician
Pharmacist UAN	0864-9999-18-082-L07-P	0864-9999-18-082-L07-P
Credits	1 CPE Hours = 0.1 CEUs	1 CPE Hours = 0.1 CEUs
Release Date	October 27 th 2018	October 27 th 2018
Expiration Date	October 27 th 2019	October 27 th 2019

ACCREDITATION



HOW TO OBTAIN CREDITS

- 1 Create your LP3 Account
- 2 Register for WCC 2018 Workshops
- 3 Note the **Tacking Code** at the **END OF THE PRESENTATION**
- 4 Submit a completed **Evaluation** (within 14 days) online for **each Workshop**.
- 5 Statement of credits will be provided within 30 days.

ANNE MARIE PINARD, MD



- Anesthesiologist, CHU de Québec-Université Laval Pain Clinic in Québec City, Canada
- Associate Professor, Anesthesiology and Intensive Care Department, Laval University
- Researcher, Center for Interdisciplinary Research in Rehabilitation and Social Integration (CIRRS)
- Master degree in Educational Technology

DISCLOSURES

I have the following financial relationships to disclose:

- Speaker for: Paladin Labs (2017-18), Purdue Pharma (2017), and Allergan Canada (2018)
- External Advisor for: Paladin Labs (2017) and Purdue Pharma (2018)
- Grant/Research support from: Purdue Pharma (2017) and MEDISCA Inc. (2018)
- Honoraria from: Paladin Labs (2017-18), Purdue Pharma (2017), Allergan Canada (2018), MEDISCA Inc. (2018)

I will discuss off label use and/or investigational use in my presentation.

UNIVERSITÉ LAVAL



Marc Robitaille, Université Laval

WHO AM I?

As a Clinician

- Anesthesiologist by training
- Clinician in the Chronic Pain Clinic at CHU de Québec-Université Laval in Québec City

As an Associate Professor

- Program Director for Fellowship in Chronic Pain
- Chairperson of the Educational Leadership Chair in Chronic Pain Management

LEARNING OBJECTIVES

PHARMACISTS

1. Identify the basic principles of **percutaneous compounded prescriptions** in a specific chronic pain condition
2. Relate the **different drugs** used successfully in clinical practice
3. Apply the **precautionary principle** for prescription
4. Recognize critical **information to provide the patient**

LEARNING OBJECTIVES

PHARMACY TECHNICIANS

1. Evaluate the objectives and benefits of percutaneous compounded preparations for the treatment of chronic pain.
2. Identify different drugs classes commonly used in pain management.
3. Recognize critical information to be communicated to the patient.

THE BURDEN OF CHRONIC PAIN



CLINICAL CASE #1: STABBING PAIN IN THE BACK



CLINICAL CASE #1: STABBING PAIN IN THE BACK

PATIENT INFORMATION

- 45 year old woman
- Works as a secretary
- A lot of responsibilities
- A lot of stress
- No chronic illness



CLINICAL CASE #1: STABBING PAIN IN THE BACK

IN THE LAST 2 YEARS:

- Pain in her upper back and neck
- Feels like a “burning dagger”
- Compromised sleep
- Often associated with headache
- Numbness sensation in right arm
- Had to take sick leave 3 times in the last 2 years



CLINICAL CASE #1: STABBING PAIN IN THE BACK

PHYSICAL EXAM

- Stiffness in cervical movements
- Trigger points on right side:
 - Levator scapulae
 - Superior trapezius
 - Rhomboid
- Neuro exam: Normal
- X-ray and MRI: Normal



CLINICAL CASE #1: STABBING PAIN IN THE BACK

PAST INTERVENTIONS

- NSAIDs
- Muscle relaxants
- Pregabalin
- Facet joint infiltration: Helped for 3 days...
- Just started physiotherapy (\$\$\$)



CLINICAL CASE #1: STABBING PAIN IN THE BACK

TREATMENT OPTIONS

- Other muscle relaxants?
- NSAIDs?
- Opioids?




CLINICAL CASE #1: STABBING PAIN IN THE BACK

**What about personalized
treatment?**

COMPOUNDED PERCUTANEOUS MEDICATION

BASIC PRINCIPLES



CLINICAL CASE #1: STABBING PAIN IN THE BACK

BACK TO OUR PATIENT

- Best Rx classes for her condition?
 - Other muscle relaxants
 - NSAIDs
 - Opioids



CLINICAL CASE #1: STABBING PAIN IN THE BACK

- Do we have to treat or prevent secondary sensitization?

YES!

- After 2 years of pain, there are certainly changes due to spinal and cerebral plasticity

HOW TO PRESCRIBE...

OR WHAT I TEACH MY COLLEAGUES AND STUDENTS!



HOW TO PRESCRIBE...

OR WHAT I TEACH MY COLLEAGUES AND STUDENTS!

- Example: Ketoprofen
- Usual po dose: Ketoprofen 75 mg TID = 225 mg daily max
- Topical preparation: Ketoprofen 3% = 3 g in 100 g
(30 mg per 1 g of preparation)
- If using 2 g TID: $60 \text{ mg} \times 3 = 180 \text{ mg}$

HOW TO PRESCRIBE...

OR WHAT I TEACH MY COLLEAGUES AND STUDENTS!

In this case, lower than the safety margin, but...

- Sometimes dosage strengths are higher for percutaneous dosage forms than oral dosage forms.
- Absorption is never 100% for skin, around 20% max if the skin is intact

YOU MUST BE VERY CAREFUL!

HOW TO PRESCRIBE...

OR WHAT I TEACH MY COLLEAGUES AND STUDENTS!

- Base
- Dose
- Total amount and fractions
- Metered pump
- # of gram per use, min and max # of use daily

CLINICAL CASE #1: STABBING PAIN IN THE BACK

NSAID

- Ketoprofen is a good choice
- It is very lipophilic
- In general, Ketoprofen 2-5%



CLINICAL CASE #1: STABBING PAIN IN THE BACK

MUSCLE RELAXANT

- Baclofen is very interesting, very effective!
- Central and peripheral action
- Unfortunately expensive...
- In general, Baclofen 2-3%



CLINICAL CASE #1: STABBING PAIN IN THE BACK

LOCAL ANESTHETIC

- Lidocaine is a good compromise
- Bupivacaine lasts a lot longer, but very expensive...
- Use a dosing pump
- In general, Lidocaine 5-10%



CLINICAL CASE #1: STABBING PAIN IN THE BACK

TRY TO CURB CENTRAL SENSITIZATION

- NMDA is the target!
- Ketamine is a good choice
- Be careful with dosage strength
- Abundant literature
- In general 4-8%



CLINICAL CASE #1: STABBING PAIN IN THE BACK

- Transdermal preparation in PLO base
- Metered pump 0.5g/pump, 1000 g total, 100 g/service
 - Ketoprofen 3%
 - Ketamine 7%
 - Lidocaine 7%
 - Baclofen 2%
- 0.5 g TID on trigger points and 0.5 g TID cervical spine
- Massage for at least 1 min on TP
- Purpose: To reduce muscle spasms and cervical spine pain



ADVICE FOR PATIENTS



CLINICAL CASE #2: CRPS



CLINICAL CASE #2: CRPS

COMPLEX REGIONAL PAIN SYNDROME (CRPS)

- Rare but serious disease
- Typically occurs in response to trauma or surgery
- Severe neuropathic and nociceptive pain, stiffness, skin changes, vasomotor abnormalities..
- Treatment: MOVEMENT!



CLINICAL CASE #2: CRPS

PATIENT INFORMATION

- 35 year old patient
- Diabetic Type 2, poorly controlled
- HTA
- Very intolerant to pain killers
- Distal radius fracture
- Closed reduction with pins
- Removed cast 4 month ago, bad evolution...



CLINICAL CASE #2: CRPS

PHYSICAL EXAM

- Severe left hand edema
- Severe diffuse allodynia
- Red hand, but rather cold
- Very sensitive to cold
- Significant stiffness (hand/wrist)
- Fear to move (Kinesiophobia)



CLINICAL CASE #2: CRPS

HOW DO WE HELP THIS PATIENT WITH A TOPICAL TREATMENT?

**Targets when
addressing
chronic pain**

- Nociceptive pain
- Neuropathic pain
- Peripheral and central sensitization
- Modulation of descending pain pathways
(usually per os)

CLINICAL CASE #2: CRPS

USEFUL AGENTS IN THE MANAGEMENT OF **NOCICEPTIVE PAIN**

- Local anesthetics
- NSAIDs
- Sympatholytic agents (also for neuropathic pain)
- Opioids
- ...

CLINICAL CASE #2: CRPS

USEFUL AGENTS IN THE MANAGEMENT OF **NEUROPATHIC PAIN**

- Anticonvulsants (Na⁺ channel blocker)
- Ca⁺⁺ channel blocker
- Local anesthetic (Na⁺ channel blocker)
- Opioids
- Tricyclic antidepressant
- Sympatholytic agents
- ...


CLINICAL CASE #2: CRPS

USEFUL AGENTS IN THE MANAGEMENT OF **PERIPHERAL AND CENTRAL SENSITIZATION**

- NMDA receptor antagonist +++
- Anticonvulsants (Na⁺ channels blocker)
- Opioids
- Tricyclics

CLINICAL CASE #2: CRPS

CRPS

- 
- ✓ Nociceptive pain
 - ✓ Neuropathic pain
 - ✓ Peripheral awareness
 - ✓ Central sensitization

CLINICAL CASE #2: CRPS

- Nociceptive pain → Local anesthetic
- Neuropathic pain → Anticonvulsant / antidepressant + local anesthetic
- Peripheral sensitization → Local anesthetic
- Central sensitization → NMDA receptor antagonist

CLINICAL CASE #2: CRPS

POTENTIAL “RECIPE”

- Lidocaine 7%
- Ketamine 7%
- Gabapentin 4%

- Bupivacaine 3%
- Ketamine 7%
- Amitriptyline 4%

...In the appropriate base with a metered pump

OTHER CONSIDERATIONS

INTERESTING INGREDIENT: **PENTOXIFYLLINE**

- Phosphodiesterase inhibitor
- Relaxes smooth muscle (decreases vasospasms)
- A few articles in literature for CRPS
- In my experience, significantly helps in the management of CRPS and scleroderma

OTHER CONSIDERATIONS

- Clonidine
- Morphine
- Other local anesthetics
- Capsaicin
-

THERE ARE
MANY OTHER
POSSIBILITIES

OTHER CONSIDERATIONS



- Be careful
- Listen to the patient
- Read the literature
- Know the physiology
- Apply pharmacology
- Teach your patients and colleagues

BE CREATIVE!

SPECIAL THANKS

- Denis Boissinot, pharmacist in Quebec City
- My team at the pain clinic
- My patients

REFERENCES

- Argoff, C. E. (2013). Topical analgesics in the management of acute and chronic pain. Introduction. *Postgrad Med*, 125(4 Suppl 1), 3-6. doi:10.3810/pgm.2013.07.suppl.2695
- Arnstein, P. M. (2013). The future of topical analgesics. *Postgrad Med*, 125(4 Suppl 1), 34-41. doi:10.1080/00325481.2013.1110567211
- Asbill, S., Sweitzer, S. M., Spigener, S., & Romero-Sandoval, A. (2014). Compounded pain formulations: what is the evidence? *Int J Pharm Compd*, 18(4), 278-286.
- Barkin, R. L. (2013). The pharmacology of topical analgesics. *Postgrad Med*, 125(4 Suppl 1), 7-18. doi:10.1080/00325481.2013.1110566911
- Bassani, A. S., & Banov, D. (2016). Evaluation of the Percutaneous Absorption of Ketamine HCl, Gabapentin, Clonidine HCl, and Baclofen, in Compounded Transdermal Pain Formulations, Using the Franz Finite Dose Model. *Pain Med*, 17(2), 230-238. doi:10.1111/pme.12899
- Bryson, E., Asbill, S., & Sweitzer, S. (2014). Skin permeation and antinociception of topical gabapentin formulations. *Int J Pharm Compd*, 18(6), 504-511.
- Campbell, C. M., Kipnes, M. S., Stouch, B. C., Brady, K. L., Kelly, M., Schmidt, W. K., . . . Campbell, J. N. (2012). Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. *Pain*, 153(9), 1815-1823. doi:10.1016/j.pain.2012.04.014
- Casale, R., Di Matteo, M., Minella, C. E., Fanelli, G., & Allegri, M. (2014). Reduction of painful area as new possible therapeutic target in post-herpetic neuropathic pain treated with 5% lidocaine medicated plaster: a case series. *J Pain Res*, 7, 353-357. doi:10.2147/jpr.S65398
- Casale, R., Symeonidou, Z., & Bartolo, M. (2017). Topical Treatments for Localized Neuropathic Pain. *Current Pain & Headache Reports*, 21(3), 15. doi:10.1007/s11916-017-0615-y
- Cline, A. E., & Turrentine, J. E. (2016). Compounded Topical Analgesics for Chronic Pain. *Dermatitis*, 27(5), 263-271. doi:10.1097/DER.0000000000000216
- Cordero, J. A., Alarcon, L., Escribano, E., Obach, R., & Domenech, J. (1997). A comparative study of the transdermal penetration of a series of nonsteroidal antiinflammatory drugs. *J Pharm Sci*, 86(4), 503-508. doi:10.1021/js950346l
- Derry, S., Conaghan, P., Da Silva, J. A., Wiffen, P. J., & Moore, R. A. (2016). Topical NSAIDs for chronic musculoskeletal pain in adults. *Cochrane Database Syst Rev*, 4, Cd007400. doi:10.1002/14651858.CD007400.pub3
- Derry, S., & Moore, R. A. (2012). Topical capsaicin (low concentration) for chronic neuropathic pain in adults. *Cochrane Database Syst Rev*(9), Cd010111. doi:10.1002/14651858.Cd010111
- Derry, S., Rice, A. S., Cole, P., Tan, T., & Moore, R. A. (2017). Topical capsaicin (high concentration) for chronic neuropathic pain in adults. *Cochrane Database Syst Rev*, 1, Cd007393. doi:10.1002/14651858.CD007393.pub4

REFERENCES

- Derry, S., Wiffen, P. J., Kalso, E. A., Bell, R. F., Aldington, D., Phillips, T., . . . Moore, R. A. (2017). Topical analgesics for acute and chronic pain in adults - an overview of Cochrane Reviews. *Cochrane Database Syst Rev*, 5, Cd008609. doi:10.1002/14651858.CD008609.pub2
- Derry, S., Wiffen, P. J., Moore, R. A., & Quinlan, J. (2014). Topical lidocaine for neuropathic pain in adults. *Cochrane Database Syst Rev*(7), Cd010958. doi:10.1002/14651858.CD010958.pub2
- Finch, P., & Drummond, P. (2015). Topical treatment in pain medicine: from ancient remedies to modern usage. *Pain Management*, 5(5), 359.
- Glinn, M. A., Lickteig, A. J., Weber, L., Recer, S., Salske, M., Harvey, A., . . . Bell, P. (2017). Urinary Concentrations of Topically Administered Pain Medications. *J Anal Toxicol*, 41(2), 127-133. doi:10.1093/jat/bkw110
- Gudín, J. A., Brennan, M. J., Harris, E. D., Hurwitz, P. L., Dietze, D. T., & Strader, J. D. (2017). Changes in pain and concurrent pain medication use following compounded topical analgesic treatment for chronic pain: 3- and 6-month follow-up results from the prospective, observational Optimizing Patient Experience and Response to Topical Analgesics study. *J Pain Res*, 10, 2341-2354. doi:10.2147/jpr.S143513
- Gudín, J. A., Brennan, M. J., Harris, E. D., Hurwitz, P. L., Dietze, D. T., & Strader, J. D. (2018). Reduction of opioid use and improvement in chronic pain in opioid-experienced patients after topical analgesic treatment: an exploratory analysis. *Postgrad Med*, 130(1), 42-51. doi:10.1080/00325481.2018.1414551
- Hanlan, A. K., Mah-Jones, D., & Mills, P. B. (2014). Early adjunct treatment with topical lidocaine results in improved pain and function in a patient with complex regional pain syndrome. *Pain physician*, 17(5), E629-635.
- Heustess, A., Spigener, S., Sweitzer, S., Romero-Sandoval, A., & Asbill, S. (2015). Analgesic Efficacy and Transdermal Penetration of Topical Gabapentin Creams: Finding an Optimal Dose and Pre-treatment Time. *Int J Pharm Compd*, 19(2), 167-173.
- Jorge, L. L., Feres, C. C., & Teles, V. E. (2010). Topical preparations for pain relief: efficacy and patient adherence. *J Pain Res*, 4, 11-24. doi:10.2147/jpr.S9492
- Kopsky, D. J., & Hesselink, J. M. (2012). High doses of topical amitriptyline in neuropathic pain: two cases and literature review. *Pain Pract*, 12(2), 148-153. doi:10.1111/j.1533-2500.2011.00477.x
- Laferriere, A., Abaji, R., Tsai, C. Y., Ragavendran, J. V., & Coderre, T. J. (2014). Topical combinations to treat microvascular dysfunction of chronic postischemia pain. *Anesth Analg*, 118(4), 830-840. doi:10.1213/ANE.0000000000000141
- Morlion, B. (2011). Pharmacotherapy of low back pain: targeting nociceptive and neuropathic pain components. *Curr Med Res Opin*, 27(1), 11-33. doi:10.1185/03007995.2010.534446
- Peppin, J. F., Albrecht, P. J., Argoff, C., Gustorff, B., Pappagallo, M., Rice, F. L., & Wallace, M. S. (2015a). Skin Matters: A Review of Topical Treatments for Chronic Pain. Part One: Skin Physiology and Delivery Systems. *Pain Ther*, 4(1), 17-32. doi:10.1007/s40122-015-0031-0

TRACKING CODE

WCC2018PAIN

pain
Pain [peɪn]
suffer

**THANK YOU FOR LISTENING
QUESTIONS?**